Bisphosphonate-associated femoral fracture: Implications for management in patients with malignancies

Osteoporosis International

Volumn 21, Issue 4, 2010, Pages 705-708

  Napoli, N ^a,b   Novack, D ^a   Armamento Villareal, R ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Bisphosphonates; Femoral fractures; Malignancies

Indexed keywords

PAMIDRONIC ACID; PREDNISONE; ZOLEDRONIC ACID;

ADRENAL INSUFFICIENCY; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER PATIENT; CASE REPORT; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DRUG INDICATION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FEMUR SHAFT FRACTURE; FRACTURE NONUNION; HIP PAIN; HIP RADIOGRAPHY; HUMAN; INTRAMEDULLARY NAILING; JAW OSTEONECROSIS; MEDICAL DECISION MAKING; MULTIPLE MYELOMA; OSTEOPOROSIS; PRIORITY JOURNAL; RISK ASSESSMENT; SIDE EFFECT; TREATMENT DURATION;

BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; FEMORAL FRACTURES; FRACTURE FIXATION, INTRAMEDULLARY; FRACTURES, UNUNITED; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA;

EID: 77950937944     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-009-1012-0     Document Type: Article

References (19)

1. 1. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90 (3):1294-1301 (Pubitemid 40463979)
2. Armamento-Villareal R, Napoli N, Panwar V, Novack D (2006) Suppressed bone turnover during alendronate therapy for highturnover osteoporosis. N Engl J Med 355(19):2048-2050
3. Visekruna M, Wilson D, McKiernan FE (2008) Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 93(8):2948-2952
4. Odvina CV, Levy S, Rao S, Zerwekh JE, Sudhaker RD. Unusual mid-shaft fractures during long term bisphosphonate therapy. Clin Endocrinol (Oxf) 2009, March 19
5. Kyle RA, Yee GC, Somerfield MR et al (2007) American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 25 (17):2464-2472
6. Rosen LS, Gordon D, Kaminski M et al (2003) Long-term efficacy and safety of zoledronic acid compared with Pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98 (8): 1735-1744
7. Lipton A, Theriault RL, Hortobagyi GN et al (2000) Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 88(5):1082-1090
8. Cook JR (2008) Meta-analysis of effects of zoledronic acid (ZOL) on survival in metastatic bone disease (MBD). Abstract, 2008 ASCO Annual Meeting
9. Lenart BA, Neviaser AS, Lyman S et al. (2009) Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 20:1353-1362
10. Schneider JP (2006) Should bisphosphonates be continued indefinitely? An unusual, fracture in a healthy woman on longterm alendronate. Geriatrics 61(1):31-33
11. Lenart BA, Lorich DG, Lane JM (2008) Atypical fractures of the femoral diaphysis in postmenopausal, women taking alendronate. N Engl J Med 358(12):1304-1306
12. Kwek. EB, Goh SK, Koh JS, Png MA, Howe TS (2008) An emerging pattern of subtrochanteric stress fractures: a long-term, complication of alendronate therapy? Injury 39(2):224-231
13. Goh SK, Yang KY, Koh JS et al (2007) Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 89(3):349-353
14. Mashiba T, Hirano T, Turner CH, Forwood MR, Johaston CC, Burr DB (2000) Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15(4):613-620
15. 15. Mashiba T, Turner CH, Hirano T et al (2001) Effects of high-dose etidronate treatment on microdamage accumulation and biomechanical properties in beagle bone before occurrence of spontaneous fractures. Bone 29(3):271-278 (Pubitemid 32823571)
16. Bailey AJ, Paul RG, Knott L (1998) Mechanisms of maturation and ageing of collagen. Mech Ageing Dev 106(1-2):1-56
17. Gundberg CM, Anderson M, Dickson I, Gallop PM (1986) "Glycated" osteocalcin in human and bovine bone. The effect of age. J Biol Chem 261(31): 14557-14561
18. Vashishth D, Gibson GJ, Khoury JI, Schaffler MB, Kimura J, Fyhrie DP (2001) Influence of nonenzymatic glycation on biomechanical properties of cortical bone. Bone 28(2): 195-201
19. Tang SY, Allen MR, Phipps R, Burr DB, Vashishth D (2009) Changes in non-enzymatic glycation and its association, with altered mechanical properties following 1-year treatment with risedronate or alendronate. Osteoporos Int 20(6):887-894